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STEM CELLS: BIOLOGY AND TECHNOLOGY FOR THE FUTURE
REVIEW

Immune-deficient mouse models for
analysis of human stem cells
Todd E. Meyerrose, Phillip Herrbrich, David A. Hess, and Jan A. Nolta
BioTechniques 35:1262-1272 (December 2003)

The field of murine models of xenotransplantation has grown immensely over the past two decades. The explosive growth in this
field is in part due to the fact that good in vitro methods do not exist yet to allow examination of human stem cell homing into the
bone marrow compartment versus other tissues, long-term survival of human stem cells, or differentiation into tissues outside of the
hematopoietic system. Since these important aspects of human stem cell biology can be examined in vivo using immune-deficient
mice, the number of different strains and models is constantly increasing. The current review discusses the merits and drawbacks of
each immune-deficient mouse xenograft system as it stands to date and reviews how each immune-deficient mouse model has been
used to further our knowledge of human hematopoietic stem cell biology.

SEVERE COMBINED IMMUNODEFICIENT MICE
Excellent large animal models exist for accepting human
stem cell xenografts in utero (1−6) and for studying engraftment of nonhuman primate (7−16) and canine stem cells
(17−19). However, the use of the immune-deficient mouse as
a recipient of the human stem cell graft is the most common
and cost-effective strategy available to most laboratories. One
of the first strains of immune-deficient mice to be used as a
recipient of human hematopoietic cells was the severe combined immunodeficient (SCID) strain (20,21). SCID mice
have defects in T and B cell development due to a mutation
in the gene for DNA-dependent protein kinase (DNA PK)
on chromosome 16 (22). The DNA PK gene is required for
successful rearrangement of T cell receptor (TCR) and immunoglobulin gene segments, and without it, murine T and
B lymphocytes cannot develop. The SCID mutation also confers extreme radiosensitivity, due to the inability of affected
cells to mediate repair of double-strand breaks (22−26). A
drawback to the use of SCID mice is that, in spite of their lack
of T and B cells, they do have high natural killer (NK) cell
levels. Therefore, this strain is acceptable for implantation of
solid tissues, such as fetal thymus or sections of tumor, but
single-cell suspensions can be rapidly recognized and lysed
by the murine NK cells.
The hu-PBL-SCID xenograft model was created by transplanting human peripheral blood into SCID mice (21,27−29).
In spite of the high NK cell levels in SCID mice, a portion
of the human cells did engraft. However, the human cells
that had undergone prior thymic selection in the human do-

nor became profoundly anergic in the mice (27). Human T
lymphocytes recultured from hu-PBL-SCID mice could not
respond to antigen stimulation for as long as 15−40 days after
removal from the mice (27). Tary-Lehman et al. proposed
that in the hu-PBL-SCID model, the continuous stimulation
of antimouse-reactive human T lymphocytes leads to the
exhaustion of the response, resulting in peripheral tolerance
or anergy (28,29). The induction of anergy may also be due
to the fact that murine β-2 microglobulin (β2M), associated
with the type 1 major histocompatibility complex, cannot be
recognized as a stimulatory signal by human T cells (30−32).
Thus, the human T cells may exist in a state of partial activation resulting in anergy in the mice, when supporting human
thymic tissue and antigen-presenting cells are not present.
To allow studies of functional immunity, an excellent
model, the SCID/hu mouse, was then developed by implanting fragments of human fetal liver and fetal thymus under
the renal capsule of SCID mice (33,34). The fetal liver acts
as a source of hematopoietic stem cells that mature in the
human thymic fragments. In contrast to the hu-PBL-SCID
system, SCID/hu mice have continued production of human
T lymphocytes from stem cells within the human fetal liver
(34−36). The human T lymphocytes do not cause graft-vs.host disease (GVHD), perhaps because they have undergone
positive and negative selection in the human thymus and see
the murine tissue antigens as “self,” since murine dendritic
and other antigen-presenting cells colonize the human thymus. Human CD3+ cells recovered from SCID/hu thy/liv
mice can be readily stimulated by mitogens or anti-CD3 antibodies, suggesting tolerance in vivo rather than anergy (34).
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Adult human CD34+ cells can also be infused into the fetal thymus fragment in SCID/hu mice and can subsequently
mature to functional T cells (37). The SCID/hu thy/liv system is the best xenograft model of human T cell development
that can be used currently to study functional immunity.
However, drawbacks to the use of the SCID/hu model are the
need to obtain human fetal tissues, which are not available to
all laboratories, and the requirement for surgical skill to place
the fetal tissues under the murine kidney capsule. In preliminary experiments, the transplantation of postnatal, rather than
fetal, thymus sections into the muscles of immune-deficient
mice was not as successful (X. Wang, R. Hong, and J. Nolta,
unpublished data). In addition, the lack of large numbers
of developing human T cells precludes the performance of
some types of studies in SCID/hu mice. Therefore, enhanced
models for human T lymphocyte generation or engraftment in
immune-deficient mice are still sought.
NOD/SCID MICE
An improved xenograft recipient, the nonobese diabetic
SCID [(NOD/LtSz-SCID/SCID (NOD/SCID)] mouse, was
initially derived from the SCID strain by Shultz and colleagues at The Jackson Laboratory (Bar Harbor, ME, USA).
Now the most prevalently used strain of immune-deficient
mouse, NOD/SCID mice have an excellent capacity to
engraft with human cells due to additional defects in NK
cell and macrophage function and circulating complement
(38,39). The mice must be kept in a clean barrier facility because of their extreme immune deficiencies but are very easy
to breed, with large robust litters. Transplanted human stem
cells primarily generate B lymphocytes in the NOD/SCID
microenvironment, CD34+ cells are retained, and myeloid
cells develop to a lesser extent than B lymphocytes. Human
T cells are not generated from highly purified stem cells in
adult NOD/SCID mice. Mature human T cells can survive in
some cases and undergo peripheral expansion, especially if
extremely high cell numbers are transplanted (40).
There have been reports that human T cells can be found in
the spleen, thymus, and lymph nodes of NOD/SCID mice one
month after transplantation with unseparated umbilical cord
blood cells (41). These cells may have arisen from peripheral
expansion. NOD/SCID mice are an excellent system in which
to study human B lymphocyte development, but there are few
reports of human T cell development from purified stem cells
in NOD/SCID mice, under normal transplant conditions. We
and others have been unable to achieve T cell development in
NOD/SCID mice, using 99.5% pure CD34+/CD38- cells from
human bone marrow or umbilical cord blood, potentially due
to the presence of residual NK cells in NOD/SCID mice (30).
Another problem might be that the acellular murine thymic
microenvironment could be too atrophied to allow cell seeding and development, by the time that human stem cells are
injected into the NOD/SCID recipients. These questions remain to be answered.
Civin’s group recently described a model for GVHD using
NOD/SCID mice as recipients for mature human T cells (40).
Human T cells were recovered, and a GVHD-like disease
Vol. 35, No. 6 (2003)

was observed only when high cell doses were transplanted
(40). In many cases, however, even mature T lymphocytes in
transplanted human PBL or cord blood samples can be rapidly cleared from NOD/SCID mice by unknown mechanisms.
Leakiness for NK cells appears to be a prime factor in human
T cell rejection in xenograft models, particularly the NOD/
SCID (42). In their study, the treatment of NOD/SCID mice
with an antimurine interleukin-2R beta (IL-2R β) antibody,
previously shown to decrease NK cell activity, resulted in
functional human T cells recovered from 60% of the treated
mice, in contrast to sporadic low levels in the untreated mice
(42).
Although human T cells do not develop well following
transplantation of purified hematopoietic stem cells into untreated NOD/SCID recipients, interestingly, the fetal thymus
organ culture (FTOC) works well when the thymic lobes are
harvested from fetal NOD/SCID mice. FTOC is a method
to develop T lymphocytes from human stem and progenitor
cells, in murine fetal thymic lobes grown at the liquid/air
interface. Traditionally, the murine fetal thymic lobes must
be depleted of murine thymocytes by extended culture prior
to introduction of the human cells. Laure Coulombels’ group
described a more simplified technique, in which NOD/SCID
fetal thymic lobes are used immediately after harvest, due to
the absolute lack of murine thymocytes (32). This system
has proven to be very reproducible for generating human T
lymphocytes from small numbers of highly purified human
pluripotent stem cells, which rules out peripheral expansion
of mature T cells.
The NOD/SCID strain is by far the most widely used
xenograft recipient to date. However, one drawback to the
use of NOD/SCID mice is their shortened lifespan (often
4−6 months) due to the presence of a provirus, Emv-30, on
chromosome 11, that causes thymoma (39,43). The duration
of the experiments that can be done to examine human stem
cell engraftment using NOD/SCID mice is therefore limited.
Some of the mice do live to old age, but others in each arm of
the experiment are lost to early thymoma. Therefore, if many
mice are initially transplanted per arm of each experiment, it
is possible to obtain some long-term survivors for analysis
out to 6 months posttransplantation. Many groups also use
NOD/SCID mice as recipients for human stem cells for 1−2
months, followed by a secondary transplant into the same
strain, for several more months (41,44−46).
The NOD/SCID strain was the first to be used to show that
human CD34- cells could have engraftment capacity (47,48).
This field has been interesting yet controversial. Osawa et al.
initially reported a murine CD34- cell that had full engrafting
capacity (49). In the same year, Goodell et al. characterized a
primitive “side population” (or SP) cells in mouse, monkey,
and man, that excluded the Hoechst 33342 dye, lacked CD34
expression, and had reconstitution capacity (50,51). Bhatia et
al. next demonstrated that there was a low level of engraftment and hematopoietic capacity in human CD34- cells
injected into NOD/SCID mice (52), and Fujisaka et al. confirmed this finding (53).
In those initial studies, the levels of engrafting CD34- cells
were extremely low in the NOD/SCID mice. Nakamura et al.
later demonstrated that preculture of the human CD34- cells
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with cytokines in vitro prior to transplantation greatly increased their capacity for homing and engraftment (54). Other
groups who infused unstimulated human CD34- cells saw little
to no engraftment (55). Sato et al. hypothesized that the CD34stem cells are extremely quiescent, and that some type of activation is required to cause up-regulation of CD34 expression,
and to induce the capacity to engraft a recipient mouse (56). In
the studies by their group, that activation was promoted by in
vivo treatment of donor mice with 5-FU. These studies demonstrated that CD34- cells can generate CD34+ cells, and that
stimulation of the quiescent CD34- stem cells was necessary to
allow engraftment into recipient mice.
More recently, our group used the NOD/SCID strain as
secondary recipients in studies of human CD34 reversibility.
We initially identified and functionally characterized a population of human CD45+/CD34- cells that was recovered from
the bone marrow of the long-lived immune-deficient beige/
nude/xid (BNX) mice 8−12 months after transplantation of
highly purified human bone marrow-derived CD34+/CD38stem/progenitor cells (57−59). The human CD45+ cells were
devoid of CD34 protein and mRNA when isolated from the
mice (60). However, significantly higher numbers of human
colony-forming units (CFU) and long-term culture-initiating
cells (LTCIC) per engrafted human CD45+ cell were recovered from the marrow of BNX mice than from the marrow of
human stem cell-engrafted NOD/SCID mice, where 24% of
the human graft maintained CD34 expression. In addition to
their capacity for extensive in vitro generative capacity, the
human CD45+/CD34- cells recovered from the BNX bone
marrow were determined to have secondary reconstitution
capacity and to produce CD34+ progeny following retransplantation into the NOD/SCID recipients (60). These studies
demonstrate that the human CD34+ population can act as a
reservoir for generation of CD34- cells, which can, in turn,
regenerate CD34+ cells. Expression of CD34 was therefore
shown to be reversible on reconstituting human hematopoietic stem cells.
In follow-up experiments, it was determined that human
CD34+/CD38- cells do retain CD34 expression for up to 4
months in BNX recipients. Therefore, it appears that the expression of CD34 may have been lost over time in the mice,
perhaps as the human cells in the murine marrow became
very quiescent. This data would agree with a seminal report
from Makio Ogawa’s group, who showed that in murine
stem cells, CD34 expression reflects the activation state of
hematopoietic stem cells and that this is reversible. Ogawa’s
group hypothesized that up-regulation of CD34 expression in
the murine system is an “activation event” (56). The activation to which Ogawa and colleagues refer is not likely to be
simply cell cycle induction, since both murine and human
hematopoietic cells can be identified that express high levels
of CD34, yet are very highly quiescent (59,61). The molecular nature of the activating factors that regulate induction of
CD34 expression in the 5-fluoruracil (5-FU)-treated mice
described by Sato et al. (56) remain unknown at the current time. Whether CD34 is up-regulated by an increase in
metabolic activity as the quiescent cells progress toward cell
cycle by down-regulation of cyclin-dependent kinase (CDK)
inhibitors and induction of cyclins and cell cycle regulatory
1264 BioTechniques

proteins (62), or whether one or both progeny from the initial
divisions of a CD34- cell acquire CD34 expression, is not
yet clearly defined. This question is currently a subject of
investigation in several laboratories, using both in vitro and
immune-deficient mouse xenograft systems. As with many
other areas of research requiring engraftment of primitive
hematopoietic stem cells, the NOD/SCID mouse is the strain
most commonly used in studies of CD34 expression.
NOD/SCID/β-2 MICROGLOBULIN NULL MICE
NOD/SCID/β2M null mice have a more absolute immunodeficiency than the NOD/SCID strain and have virtually no
NK cell function (63). They are very permissive for xenograft
acceptance (64,65). Committed progenitor populations, as
well as primitive stem cells, can engraft in NOD/SCID/β2M
null mice (63,66,67). Unfortunately, although it is the best
and most consistent murine xenograft model, in our experience, the NOD/SCID/β2M null strain also has a lifespan that
is even shorter than the NOD/SCID strain, due to the early
development of thymoma (39,43). The lifespan may be even
shorter than in the NOD/SCID parental strain, potentially
due to duplication of the lethal provirus to additional chromosomes, or perhaps the more profound NK cell deficiency.
However, this strain appears to be permissive for human T
cell development, in addition to B and myeloid lineages, and
can accept more mature progenitor populations in addition to
stem cells, so is well worth working with. Breeding is difficult
because the female mice often die from thymoma before they
can rear their first batch of pups. To combat the problem of
female breeders dying before the first or second litter can be
raised to maturity, we and other groups routinely foster pups
to clean but immune-competent mothers that consistently live
long enough to raise the pups to the weaning stage.
A xenograft assay based on “conditioned newborn” NOD/
SCID or NOD/SCID/β2M null mice was developed that allows longer term in vivo engraftment from human umbilical
cord blood cells than the standard assays, in which mice are
transplanted at 6−12 weeks of age (68). Four to five months
after transplantation, multilineage engraftment was demonstrated by flow cytometry and by the growth of multilineage
colonies in methylcellulose culture. Secondary transplantation of the isolated human CD45+ cells, also performed at
4−5 months posttransplantation, showed that human stem
cells had durably engrafted the newborn pups, following conditioning by busulfan and cyclophosphamide, but no radiation (68). This method, combined with fostering the newborn
and transplanted pups to allow survival of the nursing mother
while the pups mature, is an excellent example of modifying
experimental strategies to compensate for the limitations of
the xenograft model. The NOD/SCID/β2M null strain allows
the highest and most reproducible engraftment with human
cells to date, and is only limited by its short lifespan.
BEIGE/NUDE/XID MICE
The BNX mouse was the immune-deficient strain first
Vol. 35, No. 6 (2003)

reported to accept a human hematopoietic progenitor xenograft, by Kamel-Reid and Dick in 1988 (69). The BNX mice
are triple recessive mutant immune-deficient mice with a 2year lifespan and deficiencies in T, B, and NK cells. Previous
studies had examined human cell lines and solid tumors in
nude mice, but since nude mice have high NK cell levels to
compensate for their lack of T cells, a transplantation of a single-cell suspension of human hematopoietic cells would be
rapidly rejected. Another problem that had prevented the field
of human-to-murine xenotransplantation from progressing
prior to 1988 had been the lack of cytokines cross-reactive to
human stem cells in the mice. Kamel-Reid et al. described the
BNX/hu model, in which the immune-deficient mice were
injected with human interleukin 3 (IL-3), and human progenitors could survive for several months, with a primarily
myeloid differentiative capacity (69).
To avoid costly injections of cytokines every 48 hours
as previously described (69), our group co-transplanted human mesenchymal stem cells (MSCs) engineered to secrete
human IL-3, in addition to their endogenous human growth
factors (70). We had previously referred to the CD45+ celldepleted, expanded, adherent myofibroblastic layer from the
marrow as “stroma,” but the better term, mesenchymal stem
cells, reflects their capacity to differentiate into multiple
tissues (71−73). It is also of interest that MSCs have been
reported to enhance engraftment of hematopoietic stem cells
(70,74−76), and to suppress an immune reaction (77,78).
Therefore, in retrospect, the co-transplantation of human
mesenchymal stem cells with the hematopoietic stem cells
in our BNX/hu xenograft system may have been important
for reasons other than IL-3 production, since the BNX mice
can be leaky in their B cell deficiency and can also generate T
cells through extrathymic production. Yet, in spite of the leakiness of their immune systems, BNX mice have been quite
useful as xenograft recipients because they provide one of
the few models in which transplanted human hematopoietic
cells or tumors can be followed long term (79−83), due to the
normal lifespan of the mice, in contrast to the short lifespan
of NOD/SCID mice.
BNX mice are useful for detecting loss or alteration of
specific lineages or engrafting stem cell populations, following in vitro manipulation, due to their normal lifespan.
Sustained multilineage human hematopoiesis in BNX mice
can be achieved from transplanted CD34+ and CD34+/CD38progenitors. The presence of human myeloid/erythroid colony-forming progenitors, mature myeloid B cells, and T lymphoid cells can be demonstrated in the marrow of the mice
for up to 18 months. Our group capitalized on this extended
engraftment capacity to examine methods to optimize transduction and ex vivo culture of primitive human stem cells. We
demonstrated that engrafting cells are best cultured with the
ability to engage integrins on a stromal monolayer (76) or a
purified fibronectin (FN) fragment (84), to sustain the capacity for long-term hematopoiesis. In more recent studies, we
used the BNX/hu system to show that the engrafting human
stem cell pool is maintained on FN and has sustained expression of GATA-2, c-Myb, and CD34, as opposed to cells that
have only short-term engraftment capacity following suspension in culture (84a). We used the BNX system to determine
Vol. 35, No. 6 (2003)

that FLT3 ligand could partially overcome the late graft
failure that occurred in human bone marrow-derived hematopoietic stem cells cultured in suspension (85). Our group also
used the BNX system to study effects of cytokines on altering
lineage production in vivo (86,87). Therefore, the BNX/hu
xenograft system is a sensitive method to assess the capacity
of marrow and umbilical cord blood-derived stem cells to undergo multilineage, long-term differentiation in vivo.
Transplantation of human hematopoietic progenitor cells
from mobilized peripheral blood mononuclear cells, adult
bone marrow, and fetal bone marrow, were done by Turner
et al. to evaluate the capacity of each progenitor source to
produce multilineage human hematopoietic engraftment in
BNX mice (88). Fetal progenitors were found to have the
best engraftment capacity, and all lineages of blood cells, including T lymphocytes, were produced from the transplanted
stem/progenitor cells in the BNX mice.
Human T lymphocytes develop from transplanted hematopoietic stem cells in the bone marrow and livers of athymic
BNX mice. The T cells are of the phenotypes CD3+/CD4+,
CD3+/CD8+, or “double positive” CD3+/CD4+/CD8+. They
all express TCR αβ, and the Vβ repertoire is severly skewed
(86). The levels of CD3+/CD8+ cells almost always exceed
the levels of CD3+/CD4+ cells (86,87,89). These data are in
agreement with that of Mackall et al., who demonstrated that
regeneration of murine CD8+ cells occurs more readily than
CD4+ cell regeneration after transplantation in athymic mice
(90). Human T lymphocytes that develop by extrathymic
mechanisms are normally anergic following recovery from
the bone marrow of the BNX mice (87). The cells do not
respond well to stimulation in vitro after recovery from the
marrow. Co-transplantation of human interleukin 7 (huIL-7)secreting human MSCs in BNX mice significantly increased
the levels and activation status of human CD4+ cells that regenerated in the bone marrow of athymic BNX mice, to the
levels seen in normal human PBL (87).
Our group used the capacity of BNX mice to develop T
lymphocytes from transplanted purified human hematopoietic stem cells to document that stem cells capable of generating both T lymphoid and myeloid cells could arise from the
same, retroviral vector-transduced hematopoietic stem cell
(89). This data was obtained using the inverse PCR method
of clonal integration analysis before the more popular NOD/
SCID strain, discussed below, was widely available. Now, a
more common strategy using the NOD/SCID strain, which
generates human B but not T lymphocytes from purified stem
cells with normal transplantation methods, is to document
production of both B lymphoid and myeloid progenitors arising from the same stem cell (91).
One advantage to the use of BNX mice, in addition to
their 2-year lifespan, is that they lack the radiation sensitivity that is a constant problem with the most commonly used
xenograft strain, the NOD/SCID mice. NOD/SCID mice
cannot repair double-strand DNA breaks due to a mutation
in the gene for DNA PK. BNX mice do not have the SCID
mutation in DNA PK and recover from sublethal radiation
as quickly as normal mice, if kept on low-dose antibiotics in
strict barrier conditions. However, BNX mice are difficult to
breed, since only females heterozygous at the nude allele can
BioTechniques 1265
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be used, and their B cell defect is sometimes leaky, so each
recipient mouse must be screened prior to use. To avoid these
problems, we developed a novel immune-deficient mouse
strain, the nude/NOD/SCID mouse.
NUDE/NOD/SCID MICE

differentially support development of human hematopoietic
lineages. We compared engraftment of human umbilical cord
blood CD34+ progenitors in three strains of immune-deficient
mice (nude/NOD/SCID, NOD/SCID, and BNX) and obtained
highly different outcomes in human blood cell lineage survival or development, in support of this theory (Figure 1). The
proportion of each hematopoietic lineage that develops from
transplanted human hematopoietic stem and progenitor cells
in all three strains differs. NOD/SCID mice generate primarily human B lymphocytes from transplanted human CD34+
cells, while human cells of all myeloid lineages and B and T
lymphocytes develop in the bone marrow of BNX mice cotransplanted with human bone marrow CD34+ and CD34+/
CD38- progenitors and IL-3 producing MSCs, as described
above. Nude NOD/SCID mice are athymic. Therefore, as
with the BNX mice described above, only extrathymic human T cell development is possible. These extrathymically
developed human T cells are abnormal, as we have shown in
the BNX strain (91c). Nevertheless, the nude/NOD/SCID is
one of the few immune-deficient mouse strains where mature
human T cells survive following injection.
In recent studies, we used the nude/NOD/SCID strain
in comparison to the NOD/SCID strain to study tracking of
adipose-derived mesenchymal stem cells (AMSCs) into various tissues. There was no significant difference in the tissue
distribution observed when cells were introduced into either

As discussed earlier in the review, the NOD/LtSz-SCID/
SCID (NOD/SCID) strain (38) is the most common immunedeficient mouse xenograft strain used to date. The mouse
is relatively hardy, breeds well, and can be engrafted with
human hematopoietic cells to very high levels, with up to
90% of the marrow replaced, if human umbilical cord blood
is transplanted. However, a major drawback to the use of the
NOD/SCID strain, in addition to their radiation sensitivity, is
that their average lifespan is short, due to the presence of the
provirus Emv-30 on chromosome 11. Our group hypothesized
that, by bringing two copies of the nude gene (also on chromosome 11) into the NOD/SCID background, the provirus,
and thymic tissue where the thymoma arises would be eliminated from homozygous nu/nu NOD/SCID mice. We therefore extensively backcrossed nude and NOD/SCID mice over
a period of three years, monitoring for immunodeficiency
and carrying the nude gene. Nude progeny were backcrossed
to NOD/SCID females for seven generations, resulting in a
mouse that has the characteristics of NOD/SCID
mice, but lacks fur and the
life-shortening provirus.
The resulting nude/NOD/
SCID mice have a 2-year
lifespan. Engraftment of
human hematopoietic stem
cells occurs efficiently in
these mice, with levels
reaching 82% marrow replacement (91a, 91b), as
can be achieved with the
NOD/SCID parental strain.
As with many of the newer
strains of immune-deficient
mice, this strain is currently
only available from the investigators that developed
it (Nolta laboratory).
Nude/NOD/SCID mice
do not require systemic human IL-3 to allow survival
of the transplanted human
cells, as our group and John
Dick’s group have reported
to be necessary for the
BNX strain (69,70,89). It
is interesting that different
Figure 1. Lineage development from human CD34+ cells in three strains of immune-deficient mice. CD34+ progencytokine and chemokine itors were isolated from human bone marrow and one million cells were transplanted into mice of three different strains
levels likely exist in the after sublethal irradiation. Between 2 and 7 months later, the mice were harvested, and lineage analyses were performed.
various strains of immune- The percentages of each human blood cell lineage that make up the total human CD45+ compartment are shown in the
deficient mice and can pie chart for each strain. BNX, beige nude xid; NOD/SCID, nonobese diabetic severe combined immunodeficient.
1266 BioTechniques
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nude/NOD/SCID or NOD/SCID mice via intravenous, intraperitoneal, intramuscular, or subcutaneous routes. This suggests that AMSCs have the ability to navigate either through
intravenous or extravascular routes. The nude/NOD/SCID
strain allowed a longer follow-up and more reproducible data
at day 75 posttransplantation, when many of the NOD/SCID
mice had to be removed from the study due to the development of thymoma. We have not yet observed thymoma developing in nude/NOD/SCID mice, out to 2 years of observation. Nude/NOD/SCID mice therefore represent a significant
advance over the traditional NOD/SCID in that they have the
same engraftment capacities but their extended lifespan will
allow long term in vivo xenograft studies that were previously
available only in the relatively leaky BNX strain. The combination of favorable aspects of the NOD/SCID background
crossed with the nude mouse has resulted in a mouse with a
profound immune deficiency but not a shortened lifespan.
NOVEL STRAINS OF IMMUNE-DEFICIENT MICE

the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors, which are
important in lymphoid development (93,94). The mice were
reported to have a complete absence of all T, B, and NK cell
function and to live to a normal lifespan (under barrier conditions), so should allow longer-term experimentation than the
NOD/SCID strain (95). Goldman et al. demonstrated that intravenous injection of human B-lymphoblastoid cells resulted
in earlier fatal metastatic lymphoproliferative disease than in
NOD/SCID controls, possibly due to the fact that the Rag-2-/-/
γC-/- strain is more defective in NK cell function (93). Levels
of engraftment with human lymphocytes were also increased,
following injection of peripheral blood. This new strain of
immune-deficient mice therefore has advantages over other
existing strains for engraftment of human cells, and the ready
acceptance of human T cells may be useful for study of adoptive immunotherapy and other studies of the human immune
system.
The most recent immune-deficient mouse strain to be
developed is the perforin (Pfp)-deficient nonobese diabetic
(NOD)-Rag1null (NOD/LtSz-Rag1nullPfpnull) mouse (96).
These mice are devoid of an immune system and have an average lifespan of 37 weeks. They support better engraftment
by human peripheral blood mononuclear cells and umbilical
cord blood cells than the NOD/LtSz-Rag1null controls. Hu-

Several new strains have been reported recently and show
great promise for the xenograft field, although they are not
yet widely and commercially available. The newer strains are
currently available only from the investigators who have developed them.
Shultz et al. generated the NOD/
LtSz-Rag-1 null mouse, which lacks
the DNA PK mutation in the SCID
strain, and is therefore radioresistant.
Instead, it has a mutation in the Rag1
gene, important for lymphocyte gene
rearrangement. Rag1-deficient mice
cannot initiate V(D)J recombination
in immunoglobulin and TCR genes,
and therefore lack functional T and
B lymphocytes. NOD/LtSz-Rag1null
mice were also documented to be
devoid of mature T or B cells and had
low NK cell activity. They supported
high levels of engraftment with human hematopoietic stem cells and
also allowed lymphoid engraftment.
Of interest, transplanted human T
cells could be readily infected with
human immunodeficiency virus. The
mice still did develop lymphoma,
like the NOD/SCID strain, but the
onset was significantly delayed (92).
The NOD/LtSz-Rag1null strain may
therefore be suitable as xenograft Figure 2. Tissue localization of human adipose-derived mesenchymal stem cells (MSCs) in NOD/
SCID/MPSVII mice. Mice were transplanted intravenously with one million human adipose-derived
recipients for experiments in which MSCs following sublethal irradiation. Thirty days later, mice were anesthetized and perfused prior to tissue
engraftment with human cells must harvest. Samples of each tissue to be studied were embedded in Tissue-Tek® Optimal Cutting Temperature
progress longer than the short dura- (OCT) freezing media (Sakura, Torrance, CA, USA) and frozen on liquid nitrogen. Sections were made on
a cryotome and stained for β-glucuronidase enzyme activity using naphthol-AS-BI- β-D-glucuronide as the
tion possible with NOD/SCID mice.
A brilliant red color was deposited over each donor-derived cell. Slides were then counterstained
The Rag-2-/-/γC-/- mouse combines substrate.
with methyl green, to allow visualization of the host cells that lack the β-glucuronidase enzyme. An exthe Rag-2 knock-out with a null muta- ample of a kidney tissue slide stained using this method is shown. In this relatively radioresistant tissue, low
tion for the common gamma chain re- MSC seeding efficiency is observed. NOD/SCID/MPSVII, nonobese diabetic severe combined immunodeceptor, essential for signaling through ficient mucopolysaccharidosis type VII.
Vol. 35, No. 6 (2003)
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man engraftment is multilineage and includes progenitors and
CD4+ T cells. Since the lack of murine NK activity seems to
be an important factor in allowing human T cell development
in immune-deficient mice, this new strain may be important
for studying human immune function in a xenograft setting.
Another recently reported new immune-deficient mouse
strain is the NOD/SCID/MPSVII mouse (97), developed
to study the in vivo localization of xenotransplanted human
cells. To create the strain, the β-glucuronidase (GUSB) mutation of the mucopolysaccharidosis type VII (MPSVII) mouse
was backcrossed onto the NOD/SCID strain. This new strain
allows donor human or murine cells transplanted into the immune-deficient mice to be readily visualized by a bright red
substrate stain for the enzyme β-glucuronidase, of which they
have normal levels. The mutant mice give no background
for this staining, due to their enzyme deficiency. Therefore,
any donor cell with normal β-glucuronidase levels can be
quickly tracked in tissue slides (or a fluorescence-activated
cell sorting-based enzyme assay) without the need for in situ
hybridization to verify donor status. The donor cells can be
counterstained with an immunohistochemical reaction to
verify tissue or lineage type, after the enzymatic staining
(97). This model will greatly facilitate studies of human and
murine stem cell homing, tracking, and differentiation.
Our group recently used sublethally irradiated NOD/
SCID/MPSVII immune-deficient mice as recipients for
human AMSCs. Figure 2 shows the low efficiency of the
AMSC seeding process into kidney, examined 1 month after
intravenous transplantation of normal human AMSCs into
NOD/SCID/MPSVII mice. The use of this strain of mice allows more rapid quantitation of the cells than was previously
possible. In spleen tissue, 3−4 AMSCs were detected per 10×
field from the spleens of all mice tested. MSCs are known to
remain in the spleen and liver for up to 6 months and release
the protein products from retroviral vector integrants into the
bloodstream (86). Using the rapid tracking system in NOD/
SCID/MPSVII mice, it is now possible to obtain seeding efficiencies into different tissues, without the potential artifacts
of fluorescence in situ hybridization analyses.
NEW DIRECTIONS FOR THE
XENOTRANSPLANTATION FIELD
The field of human to mouse xenotransplantation is constantly evolving and improving. There are many aspects of
stem cell biology that can only be studied in vivo, and therefore the need to make these models better and more physiologically relevant for human stem cells is ongoing. A major
current challenge is to develop a xenogeneic host that allows
robust human T cell development from stem cells, without
the need for implantation of human fetal tissues. This would
allow reproducible examination of human immune function
in laboratory mice. Another challenge is to extend the lifespan of the most robustly engrafting strain, the NOD/SCID/
B2M null mouse, and/or to develop methods that allow better
breeding efficiency for this short-lived strain. New strains
such as a NOD/RAG/γC/WWv mouse can be envisioned,
which might not require damaging radiation to allow human
1268 BioTechniques

stem cell engraftment. As mentioned, new strains are being
constantly generated, with The Jackson Laboratory at the
forefront of the effort.
The new field of “stem cell plasticity” opens an entire new
realm of investigation, using xenograft models. Human hematopoietic and MSCs can be transplanted into immune-deficient mice, allowing tissues that develop through transdifferentiation or fusion to be analyzed in vivo. Xenograft systems
will therefore assist in allowing the signals that regulate stem
cell recruitment and subsequent differentiation to eventually be understood. A few of the studies already done have
demonstrated highly purified human hematopoietic stem cell
differentiation into hepatocyte-like cells, following liver injury (98,99); have shown that rat liver oval cell-derived islet
cell-like clusters or total murine bone marrow displayed the
ability to reverse hyperglycemia in diabetic NOD-SCID mice
(100,101), and also that donor murine marrow can reverse hyperglycemia in the same recipients (101); have demonstrated
that human fetal-derived neurosphere cells transplanted into
neonatal immunodeficient NOD-SCID mice proliferated,
migrated, and differentiated in a site-specific manner (102);
and finally, have demonstrated that human multipotent adult
progenitor cells can engraft to multiple tissues following
transplantation into NOD/SCID mice (103). Therefore, xenotransplantation systems pave the way for future studies using
immune-deficient mice to more fully understand mechanisms
of homing and differentiation of purified human stem cells
of different types and from different tissues to repair injury
of not only the hematopoietic system, but potentially also to
contribute to the repair of damaged organs.
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